JP2012525411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525411A5 JP2012525411A5 JP2012508649A JP2012508649A JP2012525411A5 JP 2012525411 A5 JP2012525411 A5 JP 2012525411A5 JP 2012508649 A JP2012508649 A JP 2012508649A JP 2012508649 A JP2012508649 A JP 2012508649A JP 2012525411 A5 JP2012525411 A5 JP 2012525411A5
- Authority
- JP
- Japan
- Prior art keywords
- photosensitizer
- oral
- time
- oral preparation
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003504 photosensitizing agent Substances 0.000 claims description 52
- 238000002360 preparation method Methods 0.000 claims description 28
- 230000005855 radiation Effects 0.000 claims description 16
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- -1 Solutol HS Polymers 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 230000003463 hyperproliferative effect Effects 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 206010020718 hyperplasia Diseases 0.000 claims description 5
- 206010058314 Dysplasia Diseases 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 230000009469 supplementation Effects 0.000 claims description 4
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 3
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 claims description 2
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000792859 Enema Species 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 229940079360 enema for constipation Drugs 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 230000002390 hyperplastic effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000002159 nanocrystal Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims description 2
- 239000006179 pH buffering agent Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical group [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 claims description 2
- 238000007493 shaping process Methods 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000037455 tumor specific immune response Effects 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 claims 1
- 238000011203 antimicrobial therapy Methods 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17347709P | 2009-04-28 | 2009-04-28 | |
| US61/173,477 | 2009-04-28 | ||
| PCT/US2010/032780 WO2010129340A2 (en) | 2009-04-28 | 2010-04-28 | Novel photosensitizer formulations for oral administration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525411A JP2012525411A (ja) | 2012-10-22 |
| JP2012525411A5 true JP2012525411A5 (https=) | 2014-01-23 |
| JP5802198B2 JP5802198B2 (ja) | 2015-10-28 |
Family
ID=43050758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508649A Expired - Fee Related JP5802198B2 (ja) | 2009-04-28 | 2010-04-28 | 経口投与のための新規の光増感剤製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120101427A1 (https=) |
| EP (1) | EP2424536A4 (https=) |
| JP (1) | JP5802198B2 (https=) |
| CN (1) | CN102695509A (https=) |
| WO (1) | WO2010129340A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015183346A2 (en) * | 2014-01-31 | 2015-12-03 | Washington University | Imaging and treatment of pathophysiologic conditions by cerenkov radiation |
| US9974870B2 (en) | 2014-06-09 | 2018-05-22 | Washington University | Compositions and methods for treatment and imaging using nanoparticles |
| US10456375B2 (en) | 2014-09-30 | 2019-10-29 | Biolitec Unternehmensbeteiligungs Ii Ag | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy |
| ES3011714T3 (en) | 2016-02-26 | 2025-04-08 | Biolitec Holding Gmbh & Co Kg | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy |
| ES2895851T3 (es) * | 2016-04-01 | 2022-02-22 | Trioptotec Gmbh | Dispersión de fotosensibilizador y uso de la misma |
| EP3894421A1 (en) | 2018-12-10 | 2021-10-20 | Universität Hamburg | Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy |
| FR3100247B1 (fr) * | 2019-09-02 | 2021-08-06 | Centre Nat Rech Scient | Dérivé de phénazine et ses utilisations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223494A (en) * | 1989-09-25 | 1993-06-29 | The Rockefeller University | Orally administered porphyrins to control intestinal iron absorption |
| US5514669A (en) * | 1993-09-29 | 1996-05-07 | Medical College Of Ohio | Use of photodynamic therapy to treat prostatic tissue |
| US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
| WO2000051638A1 (en) * | 1999-02-26 | 2000-09-08 | Qlt Phototherapeutics Inc. | Photodynamic therapy in combination with apoptosis inducing factors |
| AU2001258117A1 (en) * | 2000-05-08 | 2001-11-20 | The University Of British Columbia | Supports for photosensitizer formulations |
| US6558653B2 (en) * | 2001-09-19 | 2003-05-06 | Scot N. Andersen | Methods for treating periodontal disease |
| CA2466425A1 (en) * | 2001-11-09 | 2003-05-15 | Qlt Inc. | Photodynamic therapy for the treatment of hair loss |
| US20040077621A1 (en) * | 2002-08-08 | 2004-04-22 | Academia Sinica | Antioxidants |
| US20050049228A1 (en) * | 2003-09-02 | 2005-03-03 | Ceramoptec Industries Inc. | Antimicrobial photodynamic therapy compound and method of use |
| RU2406480C2 (ru) * | 2005-04-08 | 2010-12-20 | Озфарма Пти Лтд | Трансбуккальная система доставки |
| US20060264423A1 (en) * | 2005-05-20 | 2006-11-23 | Bioenvision, Inc. | Methylene Blue Therapy of Viral Disease |
| US20090285766A1 (en) * | 2005-06-13 | 2009-11-19 | National University Of Singapore | Photosensitising Composition and Uses Thereof |
| WO2007144048A2 (en) * | 2006-06-12 | 2007-12-21 | Dsm Fine Chemicals Austria Nfg Gmbh & Co. Kg | Presentation form for the oral administration of phenothiazine dyes, its production and use |
| US20070299046A1 (en) * | 2006-06-26 | 2007-12-27 | Mai Nguyen Brooks | Orally available light-independent antineoplastic compounds |
| WO2008052350A1 (en) * | 2006-11-03 | 2008-05-08 | Qlt Inc. | Photodynamic therapy for the treatment of hidradenitis suppurativa |
-
2009
- 2009-04-28 US US13/266,056 patent/US20120101427A1/en not_active Abandoned
-
2010
- 2010-04-28 WO PCT/US2010/032780 patent/WO2010129340A2/en not_active Ceased
- 2010-04-28 CN CN2010800191795A patent/CN102695509A/zh active Pending
- 2010-04-28 JP JP2012508649A patent/JP5802198B2/ja not_active Expired - Fee Related
- 2010-04-28 EP EP10772569A patent/EP2424536A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525411A5 (https=) | ||
| JP6382798B2 (ja) | 局所非水性医薬製剤 | |
| EP2429498A4 (en) | NEW ORAL FORMULATIONS OF TETRAPYRROLE DERIVATIVES | |
| CN101595217A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的1H-咪唑并[4,5-c]喹啉-4-胺类及其相关化合物的前药 | |
| JP2001247459A5 (https=) | ||
| DK2125026T3 (en) | FORMATIONS BASED ON bridged POLYCYCLIC COMPOUNDS FOR INHIBITION AND RELIEF OF DISEASES | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| JP2009535352A5 (https=) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2011525911A5 (https=) | ||
| JP2012529486A5 (https=) | ||
| JP2013501731A5 (https=) | ||
| JP2015516496A5 (https=) | ||
| JP2006501240A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| JP5802198B2 (ja) | 経口投与のための新規の光増感剤製剤 | |
| JP2015528501A5 (https=) | ||
| RU2002115406A (ru) | Соединение, обладающее свойствами высвобождения гормона роста | |
| JP2018507257A5 (https=) | ||
| JP2013035819A (ja) | 薬剤およびその使用方法 | |
| JP2022514739A5 (https=) | ||
| RU2016151973A (ru) | Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами | |
| AR048342A1 (es) | FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) | |
| JP2022553175A (ja) | がんの処置における使用のためのα－メチル－ＤＬ－チロシンのアルキルエステル | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 |